These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25921425)

  • 1. Pembrolizumab for patients with advanced melanoma.
    Burki TK
    Lancet Oncol; 2015 Jun; 16(6):e264. PubMed ID: 25921425
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab superior to ipilimumab in melanoma.
    Cancer Discov; 2015 Jun; 5(6):568. PubMed ID: 25895921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.
    Queirolo P; Spagnolo F
    Cancer Treat Rev; 2017 Sep; 59():71-78. PubMed ID: 28756306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
    Hersey P; Gowrishankar K
    Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab for the treatment of melanoma.
    Kumar SS; McNeil CM
    Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab (Keytruda) for metastatic melanoma.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538981
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.
    van der Kooij MK; Joosse A; Speetjens FM; Hospers GA; Bisschop C; de Groot JW; Koornstra R; Blank CU; Kapiteijn E
    Acta Oncol; 2017 Jan; 56(1):101-103. PubMed ID: 27911126
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma.
    Metcalfe W; Anderson J; Trinh VA; Hwu WJ
    Discov Med; 2015 May; 19(106):393-401. PubMed ID: 26105702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
    Maul LV; Weichenthal M; Kähler KC; Hauschild A
    J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Assay Predicts Response to Pembrolizumab.
    Cancer Discov; 2016 Nov; 6(11):1200. PubMed ID: 27698203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NICE guidance on pembrolizumab for advanced melanoma.
    Watson I; Dominguez PP; Donegan E; Charles Z; Robertson J; Adam EJ
    Lancet Oncol; 2016 Jan; 17(1):21-2. PubMed ID: 26621380
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy in advanced melanoma: a network meta-analysis.
    Pyo JS; Kang G
    Immunotherapy; 2017 May; 9(6):471-479. PubMed ID: 28472905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma.
    Sullivan RJ; Flaherty KT
    Nat Rev Clin Oncol; 2015 Nov; 12(11):625-6. PubMed ID: 26416151
    [No Abstract]   [Full Text] [Related]  

  • 15. Pembrolizumab for Recurrent Conjunctival Melanoma.
    Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
    JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
    [No Abstract]   [Full Text] [Related]  

  • 16. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
    Hauschild A; Eichstaedt J; Möbus L; Kähler K; Weichenthal M; Schwarz T; Weidinger S
    Eur J Cancer; 2017 May; 77():84-87. PubMed ID: 28365530
    [No Abstract]   [Full Text] [Related]  

  • 17. Crystal-induced oligoarthritis triggered by pembrolizumab, an immune checkpoint inhibitor.
    Corominas H; Badlissi F; Shmerling RH
    Joint Bone Spine; 2018 Oct; 85(5):647-648. PubMed ID: 29414722
    [No Abstract]   [Full Text] [Related]  

  • 18. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
    Hamid O
    Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719
    [No Abstract]   [Full Text] [Related]  

  • 20. PD-1 inhibitors effective in hodgkin lymphoma.
    Cancer Discov; 2015 Feb; 5(2):102-3. PubMed ID: 25656882
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.